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Introduction
End-stage renal disease (ESRD) continues to represent a worldwide public health concern. The incidence of newly-treated cases of ESRD has risen over the last decade in the United States.
1 Recent estimates by the National Institute of Diabetes and Digestive and Kidney Diseases indicate that diabetes mellitus represents the single largest cause of ESRD requiring chronic dialysis or kidney transplantation and accounts for approximately 42% of new cases of ESRD in the U.S. in 1997. 1 The incidence of ESRD in patients with Type 2 diabetes has risen sharply in recent years in many regions of the world, including the United States. [1] [2] [3] [4] [5] [6] [7] [8] The prognosis of diabetic patients with ESRD is bleak -30% of diabetic patients undergoing dialysis and 15% of diabetic patients receiving their first cadaveric kidney transplants die within two years. 9, 10 Preventing or delaying the progression of diabetic nephropathy to ESRD by dietary modification, medical therapy, and/or other means of lifestyle modification, is therefore an essential management goal.
Studies in experimental models of diabetic and nondiabetic renal disease show that losartan, a selective angiotensin II (Ang II) receptor antagonist (AIIA) reduces proteinuria and ameliorates pathological changes associated with the progression of renal disease. [11] [12] [13] [14] [15] Losartan has also been demonstrated to reduce proteinuria in diabetic and nondiabetic patients with renal disease, as well as in patients with renal transplant. [16] [17] [18] [19] Although these studies have shown a beneficial effect on proteinuria in patients with Type 2 diabetes,the RENAAL study is being performed in order to prove that blockade of the Ang II AT 1 -receptor may have a beneficial effect on the progression of renal disease by retarding deterioration of renal function and decreasing cardiovascular and overall mortality.
To further investigate the long-term renal protective effects of losartan,the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) Study was initiated in patients with Type 2 diabetes and nephropathy. The RENAAL study will investigate whether losartan, either alone or in combination with conventional antihypertensive therapy,will reduce the number of patients with Type 2 diabetes experiencing a doubling of serum creatinine, ESRD, or death compared with placebotreated patients (with or without conventional antihypertensive therapy). In addition, the study will assess the effects of losartan vs. placebo on cardiovascular morbidity, mortality, progression of renal disease (slope of the reciprocal of serum creatinine), and proteinuria, as well as the impact of losartan therapy on quality of life and healthcare resource utilisation.
Methods
This multinational, double-blind, randomised, placebo-controlled study is evaluating the renal protective effects of losartan in a total of 1513 patients with Type 2 diabetes and nephropathy. The study was initiated in 1996, and patient enrollment was completed in 1998. All patients will be followed for 3.5 years after the last patient has been randomised.To be eligible for enrollment in the study, male or female patients ranging in age from 31 to 70 years diagnosed with Type 2 diabetes must have had two qualifying urinary albumin:creatinine ratios on first morning specimen of at least 300 mg/g (or a 24-hour urine protein of greater than 500 mg) and two qualifying serum creatinines between 1.5 to 3.0 mg/dL (1.3 mg/dL for females) (Table 1) . Eligible patients with Type 2 diabetes could have been either hypertensive or normotensive. Type 2 diabetes was defined as those patients who were diagnosed after the age of 30, who did not require insulin within six months of diagnosis, and who had no history of diabetic ketoacidosis. However, if one of these criteria for Type 2 diabetes was not met, a C-peptide level must have been within normal range to confirm the diagnosis. Patients were excluded from the study if they had been diagnosed with Type 1 diabetes or nondiabetic renal disease, including renal artery stenosis. Patients with a history of heart failure, myocardial infarction, coronary artery bypass grafting, cerebral vascular accident, percutaneous transluminal coronary angioplasty, or transient ischaemic attacks within 1-12 months prior to study enrollment were excluded. Serum potassium levels <3.5 or >5.5 mEq/L, and chronic use of NSAIDs and aspirin >325 mg/day, also precluded patients from entering the study.
Statistical evaluation
The sample size calculation for this trial was based upon the assumption that the five-year rate of the first time to event of the composite endpoints of doubling of serum creatinine/ESRD/death in the placebo group would be 58% and that this rate would be reduced by 20% in the losartan group. In order to have 95% power at the 4.8% significance level (two-sided, adjusted for interim analyses), the trial required the enrollment of at least 1320 patients and follow-up of the last enrolled patient for 3.5 years.
In general, all primary efficacy analyses will be based on the intention-to-treat principle. All patients will be analysed according to the treatment to which they were randomly assigned.
A formal interim analysis is planned for efficacy when the last patient has been followed for two years or when half of the expected primary endpoints have occurred, whichever comes first. The interim analysis will be performed in accordance with recommendations from an independent Data and Safety Monitoring Board (DSMB).As a result of this interim analysis, the final α-level for declaring a significant difference between treatment groups must be 0.048. In addition to reviewing the formal interim analysis, the DSMB is charged with identifying safety issues and interpreting emerging safety study data in order to make periodic recommendations on study continuation, termination or protocol modification.
An independent, blinded endpoint committee is adjudicating all potential clinical endpoints occurring from the time of randomisation until study termination, in order to determine whether an event is a true endpoint (as per the guidelines established in the RENAAL Endpoint Adjudication Manual).
Study design
The RENAAL study began with an initial screening-treatment phase lasting six weeks (Figure 1 ). During this phase, in which placebo was not administered, hypertensive patients being treated with either an angiotensin-converting enzyme inhibitor (ACE-I) or AIIA within six weeks of trial enrollment discontinued these medications and received an alternative standard antihypertensive, (open-label diuretic, beta blocker, calcium-channel blocker [CCB], or alpha blocker) as appropriate, to control their hypertension. Hypertensive patients not being treated with an ACE-I or AIIA continued to receive their existing standard antihypertensive therapy. Patients with normal blood pressure did not receive any antihypertensive treatment during this phase. During the screening-treatment phase, patients underwent a medical history, physical examination, and electrocardiography. Electrocardiograms (ECGs) are performed in this study, not only as part of standard medical practice, but as a means to identify silent myocardial infarctions (MI), which are considered a secondary efficacy endpoint. A central ECG lab interprets all ECGs conducted throughout the study, exclusively for the detection of silent MI. Throughout the screening phase, patients also provide a random urine sample for urinalysis with microscopy, urine samples (first morning void) for determination of urinary albumin/creatinine ratio and blood samples for serum chemistry and haematology parameters. With the exception of the urinalysis with microscopy, all urine and blood assessments are performed at a central laboratory. Trough blood pressure measurements are obtained at every visit.
The screening-treatment phase has been followed by a double-blind treatment phase which will last 3.5 years after the last patient has been randomised. The double-blind phase began with the randomisation of eligible patients to either losartan (50 mg daily) or placebo groups (Day 1). Patients were randomised according to a computer-generated random allocation schedule. The randomisation was stratified based on the level of baseline albuminuria. Patients will continue to receive study therapy (losartan or placebo), in addition to their existing antihypertensive therapy, for the duration of the study. On the morning of the clinic visit, the patients are instructed not to take their antihypertensive medications, including the study drug, until trough blood pressure has been measured. If the target trough blood pressure of less than 140/90 mmHg is not achieved after the first four weeks of therapy or at any phase during the study, the dose of losartan (or placebo) is increased to two pills (i.e., 100 mg) daily, however, if the 100 mg losartan dose is not sufficient to reduce trough blood pressure below target values, additional open-label antihypertensives are added. Open-label antihypertensives include diuretics, beta-blockers, calcium channel blockers, alpha blockers or centrally-acting agents. In addition, to assist in this aspect of the study, the Steering Committee has provided blood pressure treatment guidelines to investigators. Throughout the trial, patients continue to receive standard medical care for treatment of diabetes, including, but not limited to, blood pressure monitoring, routine measurements of HbA 1c and fasting blood glucose concentrations. Patients from both losartan and placebo groups will not be permitted to receive ACE-I or other AIIAs throughout the study.
Efficacy assessments
Patients return to the clinic for assessment at one week, one month and three months, and are continuing to return at intervals of three months over the 3.5-year study duration. Several key measurements are made at these time-points, including trough sitting blood pressure and heart rate, laboratory measurements (urinary albumin/creatinine ratio, blood chemistry, and haematology),healthcare resource utilisation, and yearly urinalyses, physical examinations and ECGs. In addition, quality of life questionnaires are completed by patients at each visit in the U.S. only. A subgroup of the total patient population will be analysed with regard to 24-hour urine collections at three-month intervals for total protein excretion and creatinine clearance determinations.
The primary efficacy parameter of the RENAAL study is a composite endpoint composed of the time to first event of doubling serum creatinine, ESRD, or death. ESRD has been defined as the need for chronic dialysis or renal transplantation. 
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Secondary efficacy endpoints include the assessment of cardiovascular events (e.g. MI, stroke, death from coronary heart disease, other cardiovascular-related death, coronary or peripheral revascularisation procedures, and hospitalisation for unstable angina, or heart failure), progression of renal disease (slope of the reciprocal of serum creatinine), 20 and changes in proteinuria, as measured by the urine albumin to creatinine ratio. Tertiary efficacy endpoints include health-related quality of life (U.S. patients only), healthcare resource utilisation, and incidence of amputation. Quality of life is being assessed using the SF-36 generic health profile instrument. The SF-36 is composed of numerous domains of health-related quality of life, including, but not limited to, physical function, bodily pain, general health, social function and mental health. The EQ-5D qualityadjusted life year instrument is being used to determine whether increasing the time to first event of doubling of serum creatinine, ESRD, or death leads to greater quality-adjusted life expectancy in patients treated with losartan compared with those on placebo. 21, 22 Healthcare resource utilisation data (based on ICD-9-CM codes) will be calculated only for costly episodes of care (e.g. hospitalisations and medical procedures). Throughout the trial, the safety and tolerability of losartan is being assessed.
Baseline characteristics
One thousand, five hundred, and thirteen (1513) patients have been enrolled in the RENAAL study. Approximately 50% of these patients were taking either an ACE-I or AIIA upon entering the screening treatment phase of the study. The greatest number of patients were enrolled in North America (45.5%), followed by approximately equal numbers in Asia, Europe and Latin America ( Table  2) . The patient population is comprised of 48.6% Caucasian, 15.2% Black, 16.7% Asian, 18.2% Hispanic, and 0.2% Native American (Table 3) . Enrolled patients (63.2% male, 36.8% female) have a mean (SD) age of 59.6 (7.4) years. Urinary albumin:creatinine ratio and serum creatinine levels averaged (SD) 1867 (2699) mg/g and 1.9 (0.5) mg/dL, respectively, and mean (SD) glycosylated haemoglobin (HbA 1c ) was 8.5 (1.6) %. Mean (SD) body mass index was 29.7 (6.3) kg/m 2 . Mean (SD) systolic and diastolic blood pressures at baseline were 153 (19) and 82 (10) mmHg (MAP=106 mmHg), respectively. Retinopathy (62%), lipid disorders (53.7%), neuropathy (49.2%), and cataracts (25.0%), represented the most common concurrent conditions observed at baseline (Table 4) .
Discussion
The key factors that prompted initiation of this long-term study of losartan in patients with Type 2 diabetes and nephropathy were the high prevalence of Type 2 diabetes throughout the world, the high incidence of ESRD in diabetic patients, and the lack of conclusive data on the effect of blockade of the renin-angiotensin-aldosterone system (RAAS) on the progression of renal disease and mortality in Type 2 diabetics with nephropathy.
Worldwide,an estimated 146 million people have Type 2 diabetes. 23 By 2010, the prevalence is expected to increase approximately 1.5-fold to a projected 210 million people around the world. 23 The rate of growth of Type 2 diabetes, which is reaching epidemic proportions in many countries throughout the world,can be attributed to a longer life span,obesity,diet and reduced exercise,among other factors. [29] [30] [31] The importance of tight blood pressure control in reducing the risk of macrovascular and microvascular complications in Type 2 diabetes is illustrated by the recent findings of the United Kingdom Prospective Diabetes Study (UKPDS) and the HOT study. 31, 32 The UKPDS is a multicentre, randomised, controlled study that showed that tight blood pressure control (mean blood pressure, 144/82 mmHg) achieved a clinically important reduction in the risk of death and complications related to diabetes (e.g., non-fatal MI, angina, heart failure, renal failure, and amputations) and progression of diabetic retinopathy.The HOT study also provides evidence that strict blood pressure control plays an important role in reducing cardiovascular complications of diabetes. 32 In this study, a 51% reduction in major cardiovascular events (including MI, stroke, and cardiovascular mortality) was observed in patients with diabetes whose diastolic blood pressure was less than, or equal to 80 mmHg. In addition, Parving and colleagues demonstrated that antihypertensive therapy produced a reduction in blood pressure and albuminuria, as well as an attenuation in the decline of glomerular filtration rate (GFR) in patients with Type 1 diabetes. 29 A reduction in systemic blood pressure and the associated fall in intraglomerular pressure may be an important mechanism by which antihypertensive agents attenuate the progression of diabetic nephropathy.
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In the RENAAL patient population,baseline mean blood pressure (namely systolic blood pressure) indicates suboptimal control prior to enrollment in the study. Based on the published literature, discussed previously, and the current recommendations for controlling blood pressure in patients with diabetes, it is imperative that we aim for aggressive reductions in blood pressure in this patient population. Furthermore, it is essential that blood pressure control in both treatment groups remain comparable. Assessment of the primary efficacy parameters would be difficult, if not impossible, with unequal blood pressure control between treatment groups.
Optimal blood pressure control with different classes of antihypertensive agents have shown that the progression of diabetic nephropathy can be delayed, and the risk of cardiovascular morbidity and mortality can be reduced. It has been suggested, however, that antihypertensive drugs that block the RAAS may be more effective in delaying the progression of diabetic nephropathy than conventional antihypertensive therapies. Ang II plays an important role in the progression of renal injury through haemodynamic and nonhaemodynamic mechanisms; therefore, it is believed that blockade of the Ang II receptor would offer renal protection beyond reduction in systemic blood pressure. Studies in patients with Type 1 diabetes have shown that ACE-I effectively diminish the progression of nephropathy above and beyond their blood pressure-lowering effects. 33 Also, in Type 1 diabetics with overt nephropathy, captopril therapy produced a 50% reduction in the risk of doubling of serum creatinine and the combined endpoints of ESRD and death compared with patients treated with placebo. 34 These findings suggest that blockade of the RAAS may offer renal protection in patients with Type 1 diabetes. Limited data exists on the effects of blockade of the RAAS on the progression of diabetic nephropathy in Type 2 diabetes. Although there are some similarities in the natural history of nephropathy between Type 1 and Type 2 diabetes, patients with Type 2 diabetes are typically older, with long-standing hypertension, advanced atherosclerotic changes, insulin resistance, and a high incidence of morbidity and mortality from cardiovascular disease.
At least two studies have been conducted in normotensive, Type 2 diabetic patients which demonstrated a long-term stabilising effect of ACE-I on plasma creatinine and proteinuria. 35, 36 However, this effect was not associated with differences in glomerular filtration rate between treatment groups over the same time course. 36 Nevertheless, there are no studies with ACE-I demonstrating the beneficial effects of this class of drugs on ESRD and mortality in patients with Type 2 diabetes and kidney disease. In fact, data from the UKPDS did not show any difference between the effects of ACE inhibition and β-blockade on renal and cardiovascular endpoints. 37 The AIIAs, such as losartan, represent the newest class of drugs to treat hypertension, and they appear to offer many of the therapeutic benefits of ACE-I with a more favourable side-effect profile. [38] [39] [40] [41] Losartan is an orally active, highly specific antagonist In patients with renal disease, both with and without diabetes, it has been demonstrated that losartan reduces proteinuria to a similar extent to ACE-I. In a pilot study and subsequent follow-up study performed in hypertensive patients with renal disease, Gansevoort and colleagues found that losartan treatment (50 or 100 mg daily) lowered blood pressure, decreased urinary protein excretion, and elevated renal plasma flow to a degree comparable to that found with ACE-I. 16, 17 The anti-proteinuric effect of losartan has also been demonstrated in a double-blind, cross-over study comparing losartan with amlodipine in hypertensive patients with nondiabetic nephropathy. 18 In this study, both losartan and amlodipine significantly lowered blood pressure, but only losartan significantly reduced proteinuria after four weeks of treatment. 18 In patients with Type 2 diabetes, losartan has been shown to reduce proteinuria 45 and to reduce proteinuria similar to ACE-I. 46 In recent years,the results of large,long-term clinical trials have been published, comparing the effects of ACE inhibition with those of conventional treatment on cardiovascular morbidity and mortality. [47] [48] [49] [50] The most recently published Heart Outcomes Prevention Evaluation (HOPE) study demonstrated that the risk of cardiovascular morbidity and mortality was significantly reduced with an ACE-I. 50 It is important to note that patients similar to those enrolled in the RENAAL study were excluded from HOPE. More specifically, increased levels of urinary protein and serum creatinine that characterise the RENAAL patients were not permitted in the HOPE study. 50 Additionally, only 47% of HOPE patients were hypertensive at baseline, unlike RENAAL, where approximately 94% were hypertensive. On the contrary, cardiovascular risk factors, such as established coronary artery disease and prior MI, were notably higher among patients in the HOPE study (80% and 53%, respectively) compared with those in RENAAL (19% and 11%, respectively). 50 Therefore, when assessing the relevance of such studies as HOPE to RENAAL, it is essential to consider that the risks and benefits of blockade of the RAAS have never been established in patients with Type 2 diabetes and advanced nephropathy. The RENAAL study will address such risks as hyperkalaemia and cardiovascular disease coupled with impaired renal function in patients taking a drug which inhibits the RAAS.
There are other long-term trials, that are currently underway, which will address the effects of blockade of the RAAS in high-risk patients with hypertension.Specifically,it will be interesting to compare the prospective results of the ALLHAT 51 study with those of RENAAL. The results of ALLHAT (diabetics: n=15,281 (36%)) 52 will be more relevant to the RENAAL population, in that all patients enrolled in ALLHAT are hypertensive. In this study, all patients were treated with an antihypertensive drug, either CCB, ACE-I, alpha-blocker or diuretic. The most recent news regarding ALLHAT is the termination of the alpha-blocker arm due to a higher incidence of cardiovascular events, especially congestive heart failure. 53 To date, there is no indication that the ACE-I arm is demonstrating superiority over the other treatment groups.
Considering the fact that approximately 90% of the diabetic population consists of patients with Type 2 diabetes,the results of the RENAAL study will have important clinical implications for physicians managing patients with diabetes mellitus. RENAAL is expected to underscore the clinical benefits of effective blockade of Ang II in progression of Type 2 diabetic nephropathy,as well as to help to determine whether simply lowering blood pressure in Type 2 diabetes with standard antihypertensives is adequate to achieve maximal renal protective benefits. If the results of the RENAAL study prove that blockade of the RAAS has a beneficial effect on delaying the progression of renal disease and mortality, it is likely that losartan will complement existing therapeutic options to improve survival and quality of life as well as reduce the healthcare burden of ESRD in patients with Type 2 diabetes and nephropathy.
